SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in the SVB Securities Global Biopharma Conference and Cowen’s 43^rd Annual Health Care Conference. Details of participation are as follows:

SVB Securities Global Biopharma Conference
Company Presentation
Date: February 16, 2023
Time: 1:00 PM ET – 1:30 PM ET

Cowen’s 43^rd Annual Health Care Conference
Genetic Medicines Panel
Date: March 6, 2023
Time: 10:30 AM ET – 11:30 AM ET

A webcast of both events will be available by visiting the Investors section of Tenaya’s website.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic cardiovascular disorders, as well as for more prevalent heart conditions, through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit www.tenayatherapeutics.com.

Contacts

Investors
Michelle Corral
Vice President, Investor Relations and Corporate Communications
Tenaya Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media
Wendy Ryan
Ten Bridge Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.